Delcath Systems (NASDAQ:DCTH) Hits New 52-Week High - Time to Buy?

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) hit a new 52-week high on Wednesday . The stock traded as high as $16.44 and last traded at $15.89, with a volume of 13276 shares traded. The stock had previously closed at $16.25.

Analysts Set New Price Targets

DCTH has been the topic of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Delcath Systems in a report on Tuesday, January 14th. Stephens reissued a "buy" rating on shares of Delcath Systems in a report on Friday, October 18th. StockNews.com raised Delcath Systems from a "sell" rating to a "hold" rating in a research note on Friday, October 25th. Craig Hallum increased their price target on Delcath Systems from $18.00 to $21.00 and gave the stock a "buy" rating in a research note on Friday, January 17th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $21.00 price objective on shares of Delcath Systems in a research note on Friday, October 18th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $22.25.

Delcath Systems Stock Performance

The business has a 50 day simple moving average of $13.16 and a 200-day simple moving average of $10.74. The stock has a market capitalization of $519.51 million, a P/E ratio of -12.04 and a beta of 0.86.

Hedge Funds Weigh In On Delcath Systems

Hedge funds have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Delcath Systems in the third quarter worth about $102,000. Barclays PLC acquired a new position in Delcath Systems in the 3rd quarter worth approximately $104,000. Jane Street Group LLC purchased a new position in Delcath Systems during the 3rd quarter worth approximately $110,000. Private Advisor Group LLC acquired a new stake in Delcath Systems during the 4th quarter valued at $153,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Delcath Systems in the fourth quarter valued at $156,000. Institutional investors and hedge funds own 61.12% of the company's stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.